Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Variable Rate Preferred Invesco ETF (VRP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Invesco
  • Assets Under Management 1,520,554,100
  • Market Capitalization, $K 1,520,554
  • Shares Outstanding, K 62,600
  • 36-Month Beta 0.19
  • Price/Book 2.00
  • Price/Earnings ttm 0.00
  • Annual Dividend & Yield 1.22 (5.03%)
  • Most Recent Dividend 0.124 on 01/22/19
  • Sectors:

    ETFs - Mixed Asset

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.65 +2.71%
on 01/17/19
24.32 -0.12%
on 02/15/19
+0.58 (+2.45%)
since 01/15/19
3-Month
22.26 +9.12%
on 12/27/18
24.32 -0.12%
on 02/15/19
+0.31 (+1.29%)
since 11/15/18
52-Week
22.26 +9.12%
on 12/27/18
25.45 -4.56%
on 02/16/18
-0.96 (-3.80%)
since 02/15/18

Most Recent Stories

More News
Verona Pharma to Present at Upcoming Investor Conferences

Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today...

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment

Results from this short clinical pharmacology trial inform and support further clinical development of ensifentrine as an add-on to dual and triple COPD therapy

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD

Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Enrollment complete ahead of schedule

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update

Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma's RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference

Pre-clinical findings show RPL554 stimulates rare class III and IV CFTR mutants

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)
5 Defensive ETFs to Survive Global Market Rout

Inside the long/short ETFs that remained in the green in the recent global market rout.

RALS : 35.79 (+0.20%)
BTAL : 21.15 (-0.70%)
ALTS : 36.97 (+0.16%)
VRP : 24.29 (+0.37%)
YYY : 17.62 (+0.28%)
EWJ : 54.49 (+1.28%)
ACWI : 70.51 (+1.03%)
VGK : 52.63 (+1.54%)
EEM : 42.09 (-0.14%)
DIA : 258.65 (+1.37%)
SPY : 277.37 (+1.09%)
5 Defensive ETFs to Survive Global Market Rout

Inside the long/short ETFs that remained in the green in the recent global market rout.

RALS : 35.79 (+0.20%)
BTAL : 21.15 (-0.70%)
ALTS : 36.97 (+0.16%)
VRP : 24.29 (+0.37%)
YYY : 17.62 (+0.28%)
EWJ : 54.49 (+1.28%)
ACWI : 70.51 (+1.03%)
VGK : 52.63 (+1.54%)
EEM : 42.09 (-0.14%)
DIA : 258.65 (+1.37%)
SPY : 277.37 (+1.09%)
Verona Pharma to Present Clinical Trial Data of RPL554 for COPD Maintenance Treatment at American Thoracic Society 2018 International Conference

Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces...

VRP : 24.29 (+0.37%)
VRNA : 5.91 (-1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade VRP with:

Fund Summary

The Invesco Variable Rate Preferred ETF is based on the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The Fund will generally invest at least 90% of its total assets in preferred securities that comprise the Index. The Index is a market capitalization-weighted index designed...

See More

Top 10 Holdings

Name % Holdings
General Electric Co 3.12%
JPMorgan Chase & Co 2.62%
Wells Fargo & Co 2.06%
GMAC Capital Trust I 1.78%
JPMorgan Chase & Co 1.54%
Citigroup Capital XIII 1.48%
Wachovia Capital Trust III 1.48%
Bank of America Corp 1.40%
JPMorgan Chase & Co 1.29%
Bank of America Corp 1.29%

See More

Key Turning Points

2nd Resistance Point 24.39
1st Resistance Point 24.34
Last Price 24.29
1st Support Level 24.22
2nd Support Level 24.15

See More

52-Week High 25.45
Last Price 24.29
Fibonacci 61.8% 24.23
Fibonacci 50% 23.85
Fibonacci 38.2% 23.48
52-Week Low 22.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar